☰

Anuraag R. Kansal, Ph.D. - Publications

Affiliations: 
2002 Princeton University, Princeton, NJ 
Area:
statistical mechanics and soft condensed matter theory
Tree Info Similar researchers PubMed Report error

35 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Reifsnider OS, Kansal AR, Franke J, Lee J, George JT, Brueckmann M, Kaspers S, Brand SB, Ustyugova A, Linden S, Stargardter M, Hau N. Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure. Esc Heart Failure. PMID 32909680 DOI: 10.1002/Ehf2.12985  0.32
2019 Kaku K, Haneda M, Sakamaki H, Yasui A, Murata T, Ustyugova A, Chin R, Hirase T, Shibahara T, Hayashi N, Kansal A, Kaspers S, Okamura T. Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian population in the EMPA-REG OUTCOME Trial. Clinical Therapeutics. PMID 31561882 DOI: 10.1016/J.Clinthera.2019.07.016  0.302
2019 Reifsnider O, Kansal A, Wanner C, Lee J, Pfarr E, Koitka-Weber A, Brand S, Kuti E, Ustyugova A. SAT-296 COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE BASED ON SUBGROUP OF EMPA-REG OUTCOME Kidney International Reports. 4: S132. DOI: 10.1016/J.Ekir.2019.05.336  0.331
2018 Tafazzoli A, Kansal A, Lockwood P, Petrie C, Barsdorf A. The Economic Impact of New Therapeutic Interventions on Neuropsychiatric Inventory (NPI) Symptom Scores in Patients with Alzheimer Disease Dementia and Geriatric Cognitive Disorders Extra. 8: 158-173. PMID 29805382 DOI: 10.1159/000488140  0.325
2018 Kansal A, Reifsnider O, Todorova L, Coughlan A, Villa KF. Impact of Post-Hematopoietic Cell Transplant (HCT) Survival on Cost-Effectiveness of CPX-351 Versus 7+3 in the Treatment of Therapy-Related AML or AML-MRC in the United States Blood. 132: 5837-5837. DOI: 10.1182/Blood-2018-99-112252  0.358
2018 Webster S, Hau N, Ustyugova A, Kansal A, Reifsnider O. PDB71 - ASSESSING THE RELATIVE COST-EFFECTIVENESS OF EMPAGLIFLOZIN AND CANAGLIFLOZIN FOR THE TREATMENT OF TYPE 2 DIABETES PATIENTS WITH EXISTING CARDIOVASCULAR DISEASE IN THE UK Value in Health. 21: S130. DOI: 10.1016/J.Jval.2018.09.776  0.333
2018 Reifsnider O, Kansal A, Franke J, Lee J, George J, Brueckmann M, Kaspers S, Brand S, Ustyugova A, Linden S, Hau N. PDB63 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC HEART FAILURE BASED ON SUBGROUP OF EMPA-REG OUTCOME IN THE UNITED KINGDOM Value in Health. 21: S128. DOI: 10.1016/J.Jval.2018.09.768  0.324
2018 Kaku K, Haneda M, Sakamaki H, Yasui A, Murata T, Ustyugova AV, Chin R, Hirase T, Shibahara T, Hayashi N, Kansal A, Kaspers S, Okamura T. Pdb62 - Cost-Effectiveness Analysis Of Empagliflozin In Japan Based On Results From The Subgroup Analysis Of Asian Patients In The Empa-Reg Outcome Trial Value in Health. 21. DOI: 10.1016/J.Jval.2018.09.767  0.323
2017 Peng S, Deger KA, Ustyugova A, Gandhi P, Qiao N, Wang C, Kansal AR. Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries. Current Medical Research and Opinion. 1-33. PMID 28862479 DOI: 10.1080/03007995.2017.1375470  0.313
2017 Kansal A, Du M, Herrera-Restrepo O, Leipold R, Ryan RJ, Louie AC, Chung K. Cost-Effectiveness of CPX-351 Versus 7+3 Regimen in the Treatment of Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC) Blood. 130: 4674-4674. DOI: 10.1182/Blood.V130.Suppl_1.4674.4674  0.375
2016 Kansal A, DosSantos R, Tafazzoli A. Differences in Long-Term Patient Outcomes with Disease-Modifying Versus Symptomatic Treatments for Alzheimer’s Disease (Ad) Value in Health. 19. DOI: 10.1016/J.Jval.2016.09.460  0.301
2016 Daacke I, Kandaswamy P, Tebboth A, Kansal A, Reifsnider O. Cost-Effectiveness of Empagliflozin (Jardiance) in the Treatment of Patients with Type 2 Diabetes Mellitus (T2DM) in the UK Based on Empa-Reg Outcome Data Value in Health. 19: A673. DOI: 10.1016/J.Jval.2016.09.1876  0.316
2015 Ben-Joseph R, Bell JA, Chitnis A, Kansal A, Holly P, Paramore C, Wild H. Characterizing downstream healthcare resource utilization and costs based on prior utilization patterns of immediate-release hydrocodone. Journal of Medical Economics. 1-27. PMID 26451633 DOI: 10.3111/13696998.2015.1105810  0.302
2015 Kansal A, Kielhorn A, Dorman E, Krotneva S, Zheng Y, Patel H, Borer J. Treatment Effects On The Cost Burden Of Hospitalizations In Patients With Chronic Systolic Heart Failure Value in Health. 18. DOI: 10.1016/J.Jval.2015.03.807  0.304
2014 Zheng Y, Sorensen SV, Gonschior AK, Noack H, Heinrich-Nols J, Sunderland T, Kansal AR. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting. Clinical Therapeutics. 36: 2015-2028.e2. PMID 25438722 DOI: 10.1016/J.Clinthera.2014.09.015  0.333
2014 Clemens A, Peng S, Brand S, Brueckmann M, Kansal A, Lim J, Noack H, Sander S, Sorensen S. Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups. The American Journal of Cardiology. 114: 849-55. PMID 25103918 DOI: 10.1016/J.Amjcard.2014.06.015  0.312
2014 Guo S, Pelligra C, Saint-Laurent Thibault C, Hernandez L, Kansal A. Cost-effectiveness analyses in multiple sclerosis: a review of modelling approaches. Pharmacoeconomics. 32: 559-72. PMID 24643323 DOI: 10.1007/S40273-014-0150-1  0.346
2014 Zheng Y, Sorensen S, Palencia R, Ruffolo A, Hass B, Kansal A. Modeling the long-term costs and outcomes of antidiabetics in patients with type 2 diabetes at high risk of cardiovascular events Value in Health. 17. DOI: 10.1016/J.Jval.2014.03.1444  0.311
2013 Kansal AR, Zheng Y, Palencia R, Ruffolo A, Hass B, Sorensen SV. Modeling hard clinical end-point data in economic analyses. Journal of Medical Economics. 16: 1327-43. PMID 24032651 DOI: 10.3111/13696998.2013.838960  0.318
2013 Kansal AR, Zheng Y, Pokora T, Sorensen SV. Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation. Best Practice & Research. Clinical Haematology. 26: 225-37. PMID 23953910 DOI: 10.1016/J.Beha.2013.07.012  0.318
2013 Sorensen SV, Peng S, Monz BU, Bradley-Kennedy C, Kansal AR. A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation. Pharmacoeconomics. 31: 589-604. PMID 23615895 DOI: 10.1007/S40273-013-0035-8  0.337
2013 Kansal AR, Zheng Y, Palencia R, Ruffolo A, Hass B, Sorensen S. Methodological Approaches for Modeling Cardiovascular Events in Cost-Effectiveness Analyses Based on Outcome Trials Value in Health. 16. DOI: 10.1016/J.Jval.2013.08.1630  0.318
2012 Kadambi A, Leipold RJ, Kansal AR, Sorensen S, Getsios D. Inclusion of compliance and persistence in economic models: past, present and future. Applied Health Economics and Health Policy. 10: 365-79. PMID 23030640 DOI: 10.2165/11640590-000000000-00000  0.305
2012 Kansal AR, Sharma M, Bradley-Kennedy C, Clemens A, Monz BU, Peng S, Roskell N, Sorensen SV. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. Thrombosis and Haemostasis. 108: 672-82. PMID 22898892 DOI: 10.1160/Th12-06-0388  0.35
2012 Kansal AR, Sorensen SV, Gani R, Robinson P, Pan F, Plumb JM, Cowie MR. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart (British Cardiac Society). 98: 573-8. PMID 22422743 DOI: 10.1136/Heartjnl-2011-300646  0.317
2002 Kansal AR, Torquato S, Stillinger FH. Diversity of order and densities in jammed hard-particle packings. Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics. 66: 041109. PMID 12443179 DOI: 10.1103/Physreve.66.041109  0.459
2002 Schmitz JE, Kansal AR, Torquato S. A cellular automaton model of brain tumor treatment and resistance Journal of Theoretical Medicine. 4: 223-239. DOI: 10.1080/1027366031000086674  0.461
2002 Kansal AR, Torquato S, Stillinger FH. Computer generation of dense polydisperse sphere packings Journal of Chemical Physics. 117: 8212-8218. DOI: 10.1063/1.1511510  0.455
2002 Kansal AR, Torquato S. Prediction of trapping rates in mixtures of partially absorbing spheres Journal of Chemical Physics. 116: 10589-10597. DOI: 10.1063/1.1479718  0.432
2001 Deisboeck TS, Berens ME, Kansal AR, Torquato S, Stemmer-Rachamimov AO, Chiocca EA. Pattern of self-organization in tumour systems: complex growth dynamics in a novel brain tumour spheroid model. Cell Proliferation. 34: 115-34. PMID 11348426 DOI: 10.1046/J.1365-2184.2001.00202.X  0.428
2001 Kansal AR, Torquato S. Globally and locally minimal weight spanning tree networks Physica a: Statistical Mechanics and Its Applications. 301: 601-619. DOI: 10.1016/S0378-4371(01)00430-7  0.418
2000 Kansal AR, Torquato S, Chiocca EA, Deisboeck TS. Emergence of a subpopulation in a computational model of tumor growth. Journal of Theoretical Biology. 207: 431-41. PMID 11082311 DOI: 10.1006/Jtbi.2000.2186  0.466
2000 Kansal AR, Torquato S, Harsh IV GR, Chiocca EA, Deisboeck TS. Cellular automaton of idealized brain tumor growth dynamics. Bio Systems. 55: 119-27. PMID 10745115 DOI: 10.1016/S0303-2647(99)00089-1  0.464
2000 Kansal AR, Torquato S, Harsh GR IV, Chiocca EA, Deisboeck TS. Simulated brain tumor growth dynamics using a three-dimensional cellular automaton. Journal of Theoretical Biology. 203: 367-82. PMID 10736214 DOI: 10.1006/Jtbi.2000.2000  0.471
2000 Kansal AR, Truskett TM, Torquato S. Nonequilibrium hard-disk packings with controlled orientational order Journal of Chemical Physics. 113: 4844-4851. DOI: 10.1063/1.1289238  0.561
Show low-probability matches.